Ischemic Heart FailureCACT-IHFNCT01555320
Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure
A study testing Qishen Yiqi Dripping Pills and Qishen Yiqi dripping pills dummy in people with Ischemic Heart Failure, run by State Administration of Traditional Chinese Medicine of the People's Republic of China at 33 sites in China.
Trial summary
CACT-IHF aims to evaluate the clinical efficacy and safety of Qishen Yiqi Dripping Pills in treating ischemic heart failure. Meeting the diagnosis, inclusion and exclusion criteria, the study plans to recruit 640 cases from 35 upper class hospitals in China, who are divided into two groups (treatment and control… Read more about this study
- Who is it for?
- Ages 40 to 79 years
- Conditions the study is for
- Ischemic Heart Failure
- What is being tested?
- Qishen Yiqi Dripping Pills and Qishen Yiqi dripping pills dummy
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 640 participants
- Where
- 33 sitesChina
- Study dates
- Mar 2012to Dec 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 40 to 79
- Patients with ischemic heart failure：
- LVEF less than or equal to 45% measured by echocardiography in modified Simpson method
- History of prior myocardial infarction with or without percutaneous coronary intervention (PCI) or/and coronary artery bypass grafting (CABG);
- Coronary angiography (CAG) or coronary CTA shows more than or equal to 50% stenosis in at least one of the main coronary arteries with or without revascularization, of which the researcher thinks that it is closely related to heart failure;
- With or without dyspnea, fatigue and fluid retention (edema) etc.
Show all 9Show fewer
- History of heart failure or present with heart failure symptoms for at least 3 months;
- New York Heart Association (NYHA) Class II to IV;
- Submitted informed consent
Who cannot join
- Acute heart failure or acute exacerbation of chronic heart failure
- Those who have one of the following diseases:
- Acute coronary syndrome within 30 days
- Revascularization therapy within 6 months
- Uncontrolled hypertension with systolic pressure more than or equal to 180mmHg and/or diastolic pressure more than or equal to 110mmHg
- Second degree type 2 or worse sinoatrial/atrioventricular block without implantation of pacemaker or uncontrolled malignant cardiac arrhythmia
Show all 25Show fewer
- Dilated cardiomyopathy
- Hypertrophic obstructive cardiomyopathy
- Myocarditis
- Pulmonary artery embolism
- Severe valvular heart disease
- Pulmonary heart disease
- Stroke within 6 months
- Cardiac resynchronization therapy
- Applied diuretics, cardiotonic agents or vasodilators intravenously within 7 days
- Severe endocrine diseases such as hyperthyroidism, etc.
- History of malignant tumor
- Hemoglobin (HB )≤ 9g/dl
- Alanine aminotransferase (ALT) > 2 times the upper limit of normal
- Serum creatinine > 265 μmol/L
- Mental disorder
- Being pregnant, planning for pregnancy or breastfeeding
- Suspicious or definite allergy to intervention drugs
- Participated in other trials within 2 months
- Unable to walk autonomously due to physical disabilities
Trial locations and contacts
33 sites in 1 country.
33 sites in 1 country
China33 sites, 33 recruiting
- Recruiting
The First Affiliated Hospital of Anhui University of TCM
Anhui
Zhengbin Shao, Dr., shaozhengbin@126.com
Xiaohua Dai, Dr.
- Recruiting
252 Hospital of Chinese People's Liberation Army
Baoding, Hebei
Xuebin Cao, Dr., cxb13633227588@126.com
Xuebin Cao, Dr.
- Recruiting
Beijing Hospital of Traditional Chinese Medicine
Beijing, Beijing Municipality
Yao Han, Dr., Hanyao1212@126.com
Hongxu Liu, Prof
- Recruiting
Fuwai Hospital
Beijing, Beijing Municipality
Bingqi Wei, Dr., weibing918q@sina.com
Jian Zhang, Prof
- Recruiting
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Beijing, Beijing Municipality
Yang Miao, Dr., Miya9@163.com
Yang Miao, Dr.
- Recruiting
Dong Fang Hospital
Beijing
Jinjin Lu, Dr., Lu2008jinjin@126.com
Yang Wu, Dr.
- Recruiting
The Affiliated Hospital To Changchun University of Chinese Medicine
Changchun, Jilin
Yudan Tian, Dr., 30880356@qq.com
Yue Deng, Dr.
- Recruiting
The First Hospital of Jilin University
Changchun, Jilin
Yaqiu Jiang, Dr., yaqiujiang@163.com
Yaqiu Jiang, Dr.
- Recruiting
Teaching Hospital of Chengdu University of TCM
Chengdu, Sichuan
Li Jiang, Dr., cdwwx729@163.com
Weixing Wang, Dr.
- Recruiting
Guangdong Provincial Hospital of TCM
Guangdong, Guangdong
Xiaogang Sheng, Dr., shengxiaogang1@sina.com.cn
Huanlin Wu, Prof
- Recruiting
Second Affiliated Hospital of TCM College Guiyang
Guiyang, Guizhou
Tingchun Wu, Dr., 649164263@qq.com
Tao Xu, Dr.
- Recruiting
The 1st Affiliated Hospital of Heilongjiang Traditional Chinese Medicine University
Heilongjiang, Heilongjiang
Yan Wang, Dr., 19911737@qq.com
Yang Li, Dr., 19911737@qq.com
- Recruiting
The Affiliated Nanhua Hospital of Nanhua University
Hengyang, Hunan
Huan Liu, Dr.
Xiaofeng Ma, Dr.
- Recruiting
The Affiliated Hospital of Jiangxi University of TCM
Nanchang, Jiangxi
Peng Deng, Dr., dengpeng615@sina.com
Zhongyong Liu, Dr.
- Recruiting
Jiangsu Province Traditional Chinese Medicine Hospital
Nanjing, Jiangsu
Bo Zhu, Dr., najahannah@sina.com
Xiaohu Chen, Dr.
- Recruiting
Nanjing Hospital of T.C.M
Nanjing, Jiangsu
Zhongxing Shao, Dr., Szx790102@sohu.com
Ning Gu, Dr.
- Recruiting
Shandong Province Traditional Chinese Medicine University Affiliated Hospital
Shandong, Shandong
Yunlun Li, Dr., liyunlun@163.com
Yitao Xue
- Recruiting
Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School
Shanghai, Shanghai Municipality
Qingfen Zhou, Dr., zhouqingfen@hotmail.com
Fengru Zhang, Dr.
- Recruiting
Shanghai Shuguang Hospital
Shanghai, Shanghai Municipality
Yongming Liu, Dr., liuyongming@foxmail.com
Xiaolong Wang, Dr.
- Recruiting
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Shenyang, Liaoning
Ying Yang, Dr., Yang_ying_2002@sina.com
Fengrong Wang, Dr.
- Recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning
Tao Ding, Dr., chensn@sj-hospital.org
Suning Chen, Prof
- Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning
Haiyan Shan, Dr., shanhy024@163.com
Xiaojuan Bai, Dr.
- Recruiting
The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Shenyang, Liaoning
Donghai Wang, Dr., fine_dongbo@163.com
Bo Dong, Dr.
- Recruiting
Traditional Chinese Medicine Hospital of Shan Xi Province
Taiyuan, Shanxi
Tianfu Niu, Dr., niutianfu2584@sina.com
Tianfu Niu, Dr.
- Recruiting
Affiliated Hospital of Medical College of Chinese People's Armed Police Forces
Tianjin, Tianjin Municipality
Jun Tian, Dr., Tianjun6666@hotmail.com
Tiemin Jiang, Dr.
- Recruiting
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Tianjin, Tianjin Municipality
Yazhu Hou, mreleven@163.com
Jingyuan Mao, Dr.
- Recruiting
Second Affiliated Hospital of Tianjin University of TCM
Tianjin, Tianjin Municipality
Tao Wang, Dr., Wangtao973@163.com
Yingqiang Zhao, Dr.
- Recruiting
The 2nd Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality
Ruyu Yuan, Dr., tjcardio@gmail.com
Ruyu Yuan, Dr.
- Recruiting
Tian Jin Chest Hospital
Tianjin, Tianjin Municipality
Jie Geng, Dr., gengjie_1973@126.com
Shutao Chen, Dr.
- Recruiting
Tianjin Academy of Traditional Chinese Medicine Affliated Hospital
Tianjin, Tianjin Municipality
Chuanhui Huang, Dr., huangchuanhui66@sina.com
Ruihong Fan, Dr.
- Recruiting
Traditional Chinese Medical Hospital of Xinjiang Uyghur Autonomous Region
Ürümqi, Xinjiang
Dongqing An, Dr., wxf87112008@163.com
Xiaofeng Wang, Dr.
- Recruiting
Second Affiliated Hospital of Shaanxi University of Chinese Medicine
Xianyang, Shaanxi
Jing Qi, 404317104@qq.com
Yonggang Wang, Dr.
- Recruiting
The First Affiliated Hospital of Henan University of TCM
Zhengzhou, Henan
Tinghai Du, Dr., dth2010@163.com
Mingjun Zhu, Dr.
About this study
Official title: Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure (CACT-IHF) A Randomized, Double-blind, Multicenter, Placebo-controlled Trial
CACT-IHF aims to evaluate the clinical efficacy and safety of Qishen Yiqi Dripping Pills in treating ischemic heart failure. Meeting the diagnosis, inclusion and exclusion criteria, the study plans to recruit 640 cases from 35 upper class hospitals in China, who are divided into two groups (treatment and control group) by central randomization service. The treatment group will be administrated with one bag of Qishen Yiqi Dripping Pills (0.52g/bag) three times a day in addition to standardized western medications. Whereas the control group will be given one bag of Qishen Yiqi Dripping Pills dummy (0.52g/bag) three times a day in addition to standardized western medications. Efficacy indicators include primary indicator (6 minute walk test) and secondary indicators: composite endpoint consisting of all-cause death, emergency/re-admission to hospital due to HF, frequency of re-admission due to cardiovascular disease, acute coronary syndrome, severe arrhythmia, cardiac shock, revascularization, stroke, pulmonary embolism and peripheral vascular incidences, etc.; Brain Natriuretic Peptide; echocardiography; cardiothoracic ratio; NYHA cardiac function classification; Minnesota life quality scale; scores from the four traditional chinese medicine (TCM) diagnostic methods). Other indicators include blood cholesterol, triglyceride, high density cholesterol and low density cholesterol. Safety indicators include blood pressure, heart rate, blood and urine routine tests, liver and renal function tests, serum electrolytes, electrocardiogram and adverse events. All of the patients will receive interventional drug treatment for 6 months. Follow up is needed on the 1st, 3rd, 6th, 9th, 12th month after recruitment. All patients will be followed up until the end of study (Refers to the 12th month of the last case recruited into the study).
- Conditions
- Ischemic Heart Failure
- Being tested
- Qishen Yiqi Dripping Pills, Qishen Yiqi dripping pills dummy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Qishen Yiqi Dripping PillsDrug
One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
Qishen Yiqi dripping pills dummyDrug
One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
| Study group | Role | What they receive |
|---|---|---|
| Qishen Yiqi dripping pills dummy | Placebo comparator | Not described Receives: Drug: Qishen Yiqi dripping pills dummy |
| Qishen Yiqi Dripping Pills | Experimental | Not described Receives: Drug: Qishen Yiqi Dripping Pills |
What is being measured
The primary outcome is the main question the study is designed to answer.
6MWT distance
Measured: 0 month
6MWT
Measured: 3rd month
6MWT
Measured: 6th month
Secondary outcomes (8)
Composite endpoint
all-cause death, frequency of emergency/re-admission to hospital due to HF, frequency of re-admission due to cardiovascular disease, acute coronary syndrome, severe arrhythmia, cardiac shock, revascularization, stroke, pulmonary embolism and peripheral vascular incidences, etc.
Measured: 1st,3rd,6th,9th,12th month
Brain natriuretic peptide (BNP)
Measured: 0,6th month
Echocardiography
Measured: 0,6th month
Cardiothoracic Ratio(CR)
Measured: 0,6th month
Cardiac function classification, NYHA
Measured: 0,1st,3rd,6th,9th,12th month
Minnesota life quality scale
Measured: 0,1st,3rd,6th,9th,12th month
Scores from the four TCM diagnostic methods
Measured: 0,1st,3rd,6th,9th,12th month
blood and urine routine tests,liver and renal function tests,serum electrolytes,electrocardiogram (ECG)
Measured: 0,3rd,6thmonth
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2012 (estimated)
- Study startMar 2012
- Primary completionSep 2013 (estimated)
- Study completionDec 2013 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Ischemic Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 640 participants (estimated)
Sponsor and investigators
- Lead sponsor
- State Administration of Traditional Chinese Medicine of the People's Republic of China
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Jingyuan Mao, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Investigators
- Jingyuan Mao, Dr., Principal investigator, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01555320
- Sponsor's protocol ID
- 201007001-02
- Acronym
- CACT-IHF
- Status last verified
- Mar 2013
- First submitted
- 29 Feb 2012
- Last updated
- 20 Mar 2013
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Zhou Z, Wang S, Du Y, Zhao Z, Bi Y, Su Q, Hou Y, Wang X, Mao J. Effect of Qishen Yiqi Dripping Pill on Clinical Outcomes in Patients with Ischemic Heart Failure: A Post-Hoc Analysis of the CACT-IHF Randomized Trial. Drug Des Devel Ther. 2025 Nov 15;19:10163-10174. doi: 10.2147/DDDT.S556373. eCollection 2025.
PubMed 41268060Hou YZ, Wang S, Zhao ZQ, Wang XL, Li B, Soh SB, Mao JY. Clinical assessment of complementary treatment with Qishen Yiqi dripping pills on ischemic heart failure: study protocol for a randomized, double-blind, multicenter, placebo-controlled trial (CACT-IHF). Trials. 2013 May 14;14:138. doi: 10.1186/1745-6215-14-138.
PubMed 23672353
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure (CACT-IHF) A Randomized, Double-blind, Multicenter, Placebo-controlled Trial
- ClinicalTrials.gov ID
- NCT01555320
- Acronym / sponsor ID
- CACT-IHF / 201007001-02
- Conditions
- Ischemic Heart Failure
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 640 participants (estimated)
- Lead sponsor
- State Administration of Traditional Chinese Medicine of the People's Republic of ChinaOther government
- Study start
- Mar 2012
- Primary completion
- Sep 2013 (estimated)
- Study completion
- Dec 2013 (estimated)
- First posted
- 15 Mar 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CACT-IHF aims to evaluate the clinical efficacy and safety of Qishen Yiqi Dripping Pills in treating ischemic heart failure. Meeting the diagnosis, inclusion and exclusion criteria, the study plans to recruit 640 cases from 35 upper class hospitals in China, who are divided into two groups (treatment and control group) by central randomization service. The treatment group will be administrated with one bag of Qishen Yiqi Dripping Pills (0.52g/bag) three times a day in addition to standardized western medications. Whereas the control group will be given one bag of Qishen Yiqi Dripping Pills dummy (0.52g/bag) three times a day in addition to standardized western medications. Efficacy indicators include primary indicator (6 minute walk test) and secondary indicators: composite endpoint consisting of all-cause death, emergency/re-admission to hospital due to HF, frequency of re-admission due to cardiovascular disease, acute coronary syndrome, severe arrhythmia, cardiac shock, revascularization, stroke, pulmonary embolism and peripheral vascular incidences, etc.; Brain Natriuretic Peptide; echocardiography; cardiothoracic ratio; NYHA cardiac function classification; Minnesota life quality scale; scores from the four traditional chinese medicine (TCM) diagnostic methods). Other indicators include blood cholesterol, triglyceride, high density cholesterol and low density cholesterol. Safety indicators include blood pressure, heart rate, blood and urine routine tests, liver and renal function tests, serum electrolytes, electrocardiogram and adverse events. All of the patients will receive interventional drug treatment for 6 months. Follow up is needed on the 1st, 3rd, 6th, 9th, 12th month after recruitment. All patients will be followed up until the end of study (Refers to the 12th month of the last case recruited into the study).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Qishen Yiqi dripping pills dummy | Placebo comparator | Drug: Qishen Yiqi dripping pills dummy |
| Qishen Yiqi Dripping Pills | Experimental | Drug: Qishen Yiqi Dripping Pills |
Who may qualify
- Ages
- 40 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age 40 to 79
- Patients with ischemic heart failure：
- History of heart failure or present with heart failure symptoms for at least 3 months;
- New York Heart Association (NYHA) Class II to IV;
- Submitted informed consent
Key exclusion criteria (25 listed)
- Acute heart failure or acute exacerbation of chronic heart failure
- Those who have one of the following diseases:
- Cardiac resynchronization therapy
- Applied diuretics, cardiotonic agents or vasodilators intravenously within 7 days
- Severe endocrine diseases such as hyperthyroidism, etc.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Qishen Yiqi Dripping PillsOne packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months. | Drug | Qishen Yiqi Dripping Pills |
| Qishen Yiqi dripping pills dummyOne packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months. | Drug | Qishen Yiqi dripping pills dummy |
Primary outcome
6MWT distance
Time frame: 0 month
6MWT
Time frame: 3rd month
6MWT
Time frame: 6th month
8 secondary outcomes
Composite endpoint
Time frame: 1st,3rd,6th,9th,12th month
Brain natriuretic peptide (BNP)
Time frame: 0,6th month
Echocardiography
Time frame: 0,6th month
Cardiothoracic Ratio(CR)
Time frame: 0,6th month
Cardiac function classification, NYHA
Time frame: 0,1st,3rd,6th,9th,12th month
Minnesota life quality scale
Time frame: 0,1st,3rd,6th,9th,12th month
Scores from the four TCM diagnostic methods
Time frame: 0,1st,3rd,6th,9th,12th month
blood and urine routine tests,liver and renal function tests,serum electrolytes,electrocardiogram (ECG)
Time frame: 0,3rd,6thmonth
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2013.
- Derived from this study: PubMed 41268060Zhou Z, Wang S, Du Y, Zhao Z, Bi Y, Su Q, Hou Y, Wang X, Mao J. Effect of Qishen Yiqi Dripping Pill on Clinical Outcomes in Patients with Ischemic Heart Failure: A Post-Hoc Analysis of the CACT-IHF Randomized Trial. Drug Des Devel Ther. 2025 Nov 15;19:10163-10174. doi: 10.2147/DDDT.S556373. eCollection 2025.
- Derived from this study: PubMed 23672353Hou YZ, Wang S, Zhao ZQ, Wang XL, Li B, Soh SB, Mao JY. Clinical assessment of complementary treatment with Qishen Yiqi dripping pills on ischemic heart failure: study protocol for a randomized, double-blind, multicenter, placebo-controlled trial (CACT-IHF). Trials. 2013 May 14;14:138. doi: 10.1186/1745-6215-14-138.
Related trials for Ischemic Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
Not yet recruitingObservational study
Hemodynamic Evaluation of Left Atrial Pressure in Relationship to Pulmonary Capillary Wedge Pressure in Cardio Thoracic Patients
Cardiogenic Shock, Pulmonary Edema Cardiac Cause
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jingyuan Mao, Dr. principal investigator
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
33 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Qishen Yiqi Dripping Pills and Qishen Yiqi dripping pills dummy in people with Ischemic Heart Failure, run by State Administration of Traditional Chinese Medicine of the People's Republic of China at 33 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Mar 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 33 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yazhu Hou, Dr. (8622-27432325, mreleven@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
6MWT distance (time frame: 0 month). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01555320, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2013.